Corcept Therapeutics Incorporated (Nasdaq: CORT)’s Study 03 (a Phase 2 clinical trial) demonstrated with statistical significance that more patients treated with CORLUX® achieved a rapid and sustained reduction of the psychotic features of psychotic major depression (PMD) than did patients treated with placebo.
Such results were described in an article published at the Journal of Biological Psychiatry.
More prevalent than either schizophrenia or manic-depressive illness, PMD is a serious psychiatric disorder affecting three million people every year in the United States.
Due to PMD’s serious nature and the lack of approved rugs for this particular disorder, the USFDA has granted a Fast Track designation for CORLUX® for the treatment of the psychotic features of PMD.
CORLUX® is Corcept’s lead product currently in its Phase 3 clinical trials for treating the psychotic features of PMD. CORLUX® is a potent GR-II antagonist that is administered orally to PMD patients once/day for seven days, which appears to reduce the effects of the elevated and abnormal release patterns of cortisol seen in PMD.
SOURCE: PR Newswire
.jpg)
Comment Preview